Zemplar® (paricalcitol) – Expanded indications
October 18, 2016 – The FDA announced the approval of AbbVie’s Zemplar (paricalcitol) capsules for pediatric patients 10 years and older for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) stages 3 and 4 and CKD stage 5 in patients on hemodialysis or peritoneal dialysis.
Top